Page 87 - HIV/AIDS Guidelines

cerebrovasculareventsinthehighlyactiveantiretroviraltherapyera.Clin Infect Dis.Jul12011;53(1):84-91.

94. BrothersCH,HernandezJE,CutrellAG,etal.Riskofmyocardialinfarctionandabacavirtherapy:noincreasedrisk
across52GlaxoSmithKline-sponsoredclinicaltrialsinadultsubjects.J Acquir Immune Defic Syndr.May1
2009;51(1):20-28.
95. HsuePY,HuntPW,WuY,etal.Associationofabacavirandimpairedendothelialfunctionintreatedandsuppressed
HIV-infectedpatients.AIDS.Sep242009;23(15):2021-2027.
96. SatchellCS,O'HalloranJA,CotterAG,etal.IncreasedplateletreactivityinHIV-1-infectedpatientsreceivingabacavir-
containingantiretroviraltherapy.J Infect Dis.Oct2011;204(8):1202-1210.
97. KristoffersenUS,KofoedK,KronborgG,BenfieldT,KjaerA,LebechAM.Changesinbiomarkersofcardiovascular
riskafteraswitchtoabacavirinHIV-1-infectedindividualsreceivingcombinationantiretroviraltherapy.HIV Med.Nov
2009;10(10):627-633.
98. DePabloC,OrdenS,ApostolovaN,BlanquerA,EspluguesJV,AlvarezA.Abacaviranddidanosineinducetheinteraction
betweenhumanleukocytesandendothelialcellsthroughMac-1upregulation.AIDS.Jun12010;24(9):1259-1266.
99. MartinezE,LarrousseM,PodzamczerD,etal.Abacavir-basedtherapydoesnotaffectbiologicalmechanismsassociated
withcardiovasculardysfunction.AIDS.Jan282010;24(3):F1-9.
100.PalellaFJ,Jr.,GangeSJ,BenningL,etal.InflammatorybiomarkersandabacaviruseintheWomen'sInteragencyHIV
StudyandtheMulticenterAIDSCohortStudy.AIDS.Jul172010;24(11):1657-1665.
101.MartinA,AminJ,CooperDA,etal.Abacavirdoesnotaffectcirculatinglevelsofinflammatoryorcoagulopathic
biomarkersinsuppressedHIV:arandomizedclinicaltrial.AIDS.Nov132010;24(17):2657-2663.
102.JongE,MeijersJC,vanGorpEC,SpekCA,MulderJW.Markersofinflammationandcoagulationindicatea
prothromboticstateinHIV-infectedpatientswithlong-termuseofantiretroviraltherapywithorwithoutabacavir.AIDS
Res Ther. 2010;7:9.

103.PodzamczerD,FerrerE,ConsiglioE,etal.Arandomizedclinicaltrialcomparingnelfinavirornevirapineassociatedto
zidovudine/lamivudineinHIV-infectednaivepatients(theCombineStudy).Antivir Ther.Jun2002;7(2):81-90.

104.VibhagoolA,CahnP,SchechterM,etal.Triplenucleosidetreatmentwithabacavirplusthelamivudine/zidovudine
combinationtablet(COM)comparedtoindinavir/COMinantiretroviraltherapy-naiveadults:resultsofa48-weekopen-
label,equivalencetrial(CNA3014).Curr Med Res Opin.Jul2004;20(7):1103-1114.
105.StaszewskiS,KeiserP,MontanerJ,etal.Abacavir-lamivudine-zidovudinevsindinavir-lamivudine-zidovudinein
antiretroviral-naiveHIV-infectedadults:Arandomizedequivalencetrial.JAMA.Mar72001;285(9):1155-1163.
106.DrakeA,MijchA,SasadeuszJ.ImmunereconstitutionhepatitisinHIVandhepatitisBcoinfection,despitelamivudine
therapyaspartofHAART.Clin Infect Dis.Jul12004;39(1):129-132.
107.BessesenM,IvesD,CondreayL,LawrenceS,ShermanKE.ChronicactivehepatitisBexacerbationsinhuman
immunodeficiencyvirus-infectedpatientsfollowingdevelopmentofresistancetoorwithdrawaloflamivudine.Clin
Infect Dis.May1999;28(5):1032-1035.

108.SellierP,ClevenberghP,MazeronMC,etal.Fatalinterruptionofa3TC-containingregimeninaHIV-infectedpatient
duetore-activationofchronichepatitisBvirusinfection.Scand J Infect Dis.2004;36(6-7):533-535.

109.BarnasD,KoontzD,BazmiH,BixbyC,JemsekJ,MellorsJW.ClonalresistanceanalysesofHIVtype-1afterfailureof
therapywithdidanosine,lamivudineandtenofovir.Antivir Ther.2010;15(3):437-441.

110.GerstoftJ,KirkO,ObelN,etal.Lowefficacyandhighfrequencyofadverseeventsinarandomizedtrialofthetriple
nucleosideregimenabacavir,stavudineanddidanosine.AIDS.Sep262003;17(14):2045-2052.

111.BartlettJA,JohnsonJ,HerreraG,etal.Long-termresultsofinitialtherapywithabacavirandlamivudinecombinedwith
efavirenz,amprenavir/ritonavir,orstavudine.J Acquir Immune Defic Syndr.Nov12006;43(3):284-292.
112.KumarPN,Rodriguez-FrenchA,ThompsonMA,etal.Aprospective,96-weekstudyoftheimpactofTrizivir,
Combivir/nelfinavir,andlamivudine/stavudine/nelfinavironlipids,metabolicparametersandefficacyinantiretroviral-

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents F-26

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.